Novavax’s Phase III RSV Vaccine Failure Wipes Out Nearly $2bn In Value
Novavax shocked investors with negative results for its RSV vaccine in a Phase III clinical trial immunizing older adults, but promised more data – and ideas for a potential second Phase III trial – in October.
You may also be interested in...
The market landscape for drugs against respiratory syncytial virus infections, an important risk factor in premature infants and the immunocompromised, may change drastically in the future with numerous potential therapies in the pipeline.
Failure of Regeneron's anti-RSV antibody suptavumab (REGN2222) comes at a tough time for the company, as some marketed products disappoint and a long-time alliance with Sanofi comes to an end.
Sponsors have been increasingly developing vaccine candidates for the respiratory syncytial virus with an unmet need existing for infants; the advisory committee will evaluate FDA's proposed approach for developing candidates in the target population.